Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

智通财经APP获悉，再生元(REGN.US)和赛诺菲(SNY.US)联合开发的重磅疗法Dupixent(dupilumab)获美国FDA批准，用于治疗大疱性类天疱疮(BP)成人患者。根据新闻稿，Dupixent是获美国FDA批准的首款BP疗法。据悉， ...

这项发表在权威期刊的队列研究揭示了免疫治疗领域的重要发现。研究人员通过TriNetX全球数据库，对214,430例成人特应性皮炎(AD)患者进行3年随访，比较Dupilumab（一种靶向IL-4Rα的单抗）与其他系统性药物（如糖皮质激素、甲氨蝶呤等）的银屑病发生风险。

Bio-Thera Solutions & SteinCares expand partnership to commercialize biosimilars to treat inflammatory diseases across Latin America: Guangzhou, China Thursday, June 26, 2025, 12: ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

SAN FRANCISCO — Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab, according to research presented at the American ...